期刊文献+

IL-17在急性冠状动脉综合征的变化及瑞舒伐他汀的干预作用 被引量:9

Intervention of rosuvastatin in serum IL 17 of acute coronary syndrome patients
下载PDF
导出
摘要 目的观察急性冠状动脉综合征(ACS)患者血清IL一-17的变化,并探讨不同剂量瑞舒伐他汀对该因子的干预作用。方法①随机选取2011-03-01-2011-07-0l就诊于济南军区总医院急诊科及心内科的ACS患者54例、稳定型心绞痛(SA)及非冠心病患者各20例,确保基线水平一致后检测并比较其血清IL-17水平;②同时检测ACS组54例患者的血清甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高敏C反应蛋白(hs-CRP)、磷酸肌酸激酶(cK)及磷酸肌酸激酶同工酶(CK-MB)水平,并行选择性冠状动脉造影,观察其病变支数,使用多元线性回归方程分析IL-17水平与各因素的相关性;③将ACS患者54例按照病情程度随机平分为3组,给予A、B、C3种剂量的瑞舒伐他汀治疗1个月,分别检测入院时、治疗后两周及治疗后4周的血清IL-17水平,比较不同剂量组瑞舒伐他汀对该因子的干预作用。结果①3组患者基线水平包括年龄、性别、血糖、血压、吸烟情况及体质量指数等因素差异无统计学意义(P〉0.05),ACS组的IL-17水平显著高于SA组与非冠心病组(P〈0.05),SA组IL-17与非冠心病组IL-17浓度的差异无统计学意义(P〉0.05);②多元回归分析显示:血清IL-17与CRP(B=0.873)、肌钙蛋白(p=4.990)及冠状动脉病变支数(p=11.121)呈正相关(P〈0.05),TG、LDL-C、高密度脂蛋白胆固醇(HDL-C)、CK等指标未进入回归方程;③在瑞舒伐他汀治疗两周时,使用剂量越大,IL-17下降越明显(P〈0.05);在治疗4周时,3种剂量降IL-17作用差异无统计学意义(P〉0.05)。结论IL-17在ACS患者中显著升高,且与血脂及常用心血管急症检测指标(CRP、血清心肌酶等)呈正相关,随病变支数的增加而增加,可一定程度上提示血管病变的严重程度,为ACS治疗提供一个新的靶点。 To observe the serum interleukin 17 (IL 17) level of acute coronary syndrome (ACS) patients and to study the intervention of rosuvastatin in serum IL 17. Methods 54 cases including UA 18 cases, NSTEMI 18 cases and STEMI 18 cases, stable angina(SA) of 20 cases, and noncoronary heart disease of 20 cases were selected to compare the serum IL 17 levels; The correlation between IL 17 and TG, LDL C, hs CRP, CK, CK MB were an',dysed by multiple linear regression; 54 cases were divided into three groups with different doses of rosuvastatin. The effect of different doses of rosuvastatin on serum IL 17 of ACS patients had been compared.
出处 《中国急救医学》 CAS CSCD 北大核心 2012年第3期250-254,共5页 Chinese Journal of Critical Care Medicine
关键词 白细胞介素-17 急性冠状动脉综合征 瑞舒伐他汀 The base lille conditions of three groups had no differences ( P 〉 0.05 ). The serum IL 17level was significantly higher in ACS group than in two other groups ( P 〈 0. 05 ). There were nodifferences in IL- 17 between SA group and non -coronary heart disease group(P 〉0.05 ) ~)Multiple
  • 相关文献

参考文献17

  • 1Kumar A,Cannon CP.Acute coronary syndromes:diagnosis and management,part I[J].Mayo Clin Proc,2009,84(10):917-938.
  • 2Anderson JL,Adams CD,Antman EM,et al.2011 WRITING GROUP MEMBERS;ACCF/AHA TASK FORCE MEMBERS.2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].Circulation,2011,123(18):e426-579.
  • 3Ueda Y,Matsuo K,Nishio M,et al.Systemic and local factors associated with coronary plaque disruption[J].Thromb Res,2011,Epub ahead of print.
  • 4Hermus L,Schuitemaker JH,Tio RA,et al.Novel serum biomarkers in carotid artery stenosis:useful to identify the vulnerable plaque[J].Clin Biochem,2011,44(16):1292-1298.
  • 5Gaffen SL.Recent advances in the IL-17 cytokine family[J].Curr Opin Immunol,2011,23(5):613-619.
  • 6Holme I,Szarek M,Cater NB,et al.Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study[J].Eur J Cardiovasc Prev Rehabil,2009,16(3):315-320.
  • 7Wiviott SD,Cannon CP.The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy[J].Curr Opin Lipidol,2006,17(6):626-630.
  • 8Vale N,Nordmann AJ,Schwartz GG,et al.Statins for acute coronary syndrome[J].Cochrane Database Syst Rev,2011,15(6):68-70.
  • 9Long SB,Blaha MJ,Blumenthal RS,et al.Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly[J].Clin Interv Aging,2010,2011(6):27-35.
  • 10Sano T,Tanaka A,Namba M,et al.C-reactive protein and lesion morphology in patients with acute myocardial infarction[J].Circulation,2004,109(5):e36.

二级参考文献42

共引文献16

同被引文献108

  • 1尹宇杰.院前急救采用替罗非班治疗老年急性冠状动脉综合征的有效性和安全性[J].中国老年学杂志,2014,34(7):1741-1742. 被引量:2
  • 2潘胜梅,张越,张晓霞,孙振芳.多因素预测民航飞行员冠状动脉病变的研究[J].山东医药,2013,53(45):50-52. 被引量:4
  • 3尹炯,潘晓明,蒲红,吴宗贵,刘春.冠心病患者血浆脂联素水平降低[J].中华高血压杂志,2007,15(8):685-686. 被引量:13
  • 4Aspromonte N,Di Fusco SA,Latini R,et al.Natriuretic peptides in acute chest pain and acute coronary syndrome:from pathophysiology to clinical and prognostic applications.Coron Artery Dis,2013,24:33-39.
  • 5Ballantyne CM,Pitt B,Loscalzo J,et al.Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome[from the Limiting UNdertreatment of lipids in ACS with Rosuvastatin(LUNAR)Trial].Am J Cardiol,2013,111:506-509.
  • 6Chen S,Crother TR,Arditi M.Emerging role of IL-17in atherosclerosis.J Innate Immun,2010,2:325-333.
  • 7Otagiri K,Tsutsui H,Kumazaki S,et al.Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome:analysis using integrated backscatter IVUS(ELAN study).Circ J,2011,75:633-641.
  • 8Gostiljac D,Dordevic'PB,Djuric'D,et al.The importance of defining serum MMP-9concentration in diabetics as an early marker of the rupture of atheromatous plaque in acute coronary syndrome.Acta Physiol Hung,2011,98:91-97.
  • 9Bona RD,Liuzzo G,Pedicino D,et al.Anti-inflammatory treatment of acute coronary syndromes.Curr Pharm Des,2011,17:4172-4189.
  • 10Mammen AL,Amato AA.Statin myopathy:a review of recent progress.Curr Opin Rheumatol,2010,22:644-650.

引证文献9

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部